The first year of treatment for a single patient receiving chimeric antigen receptor T-cell therapy, or CAR-T, can reach $1.2 million on the high end, according to a 2023 study published in the Journal of Clinical Oncology. That figure includes the therapy itself, hospitalization, and supportive care, and it sits at the top of a cost range that runs from $500,000 to $1.2 million. As of 2024, more than 10,000 patients in the United States have received commercial CAR-T therapy, with treatment concentrated at 150 certified centers nationwide.
The price tag is forcing both Medicare and private insurers to adapt their payment models for a treatment that represents a fundamental shift in how cancer is fought. CAR-T therapy modifies a patient’s own immune cells to target and attack cancer.
Unlike chemotherapy or radiation, which attack both healthy and cancerous cells, this approach is tailored to each individual, using their immune system with greater precision. The method emerged from late-twentieth-century research into immunotherapy, building on early work that explored how T-cells could be engineered to recognize and destroy malignant cells. After clinical trials demonstrated its potential, particularly for certain blood cancers, the first regulatory approvals in the United States came in the late 2010s. The personalization that makes CAR-T so effective also makes it one of the most complex and resource-intensive treatments available.
The Price of Personalized Medicine
List prices for the two leading CAR-T therapies as of 2024 are $373,000 for Kymriah and $475,000 for Yescarta. Those figures do not include hospitalization, which can add between $50,000 and $100,000, nor the cost of supportive care. When all expenses are tallied, the Journal of Clinical Oncology study estimated the total first-year cost of care for a CAR-T patient at $500,000 to $1.2 million.
Despite these high prices, the therapy has been shown to be cost-effective for certain indications. The cost per quality-adjusted life year, or QALY, stands at approximately $150,000.
That falls within the U.S. threshold of $150,000 to $200,000 — the range economists and payers use to determine whether a treatment provides reasonable value for the money. The concentration of treatment at 150 certified centers also raises questions about geographic access. With more than 10,000 patients having received commercial CAR-T therapy as of 2024, the vast majority of Americans who might benefit do not live near one of these specialized facilities, which may limit their ability to obtain care.
Paying for Innovation: Coverage and Access
The Centers for Medicare & Medicaid Services established a new payment mechanism in August 2019 to cover CAR-T therapies under Medicare Part B, the outpatient benefit. The national coverage determination requires hospitals that administer the therapy to participate in a registry that tracks patient outcomes. This step was a first adaptation of the federal health insurance program, established in the mid-1960s for older adults and certain disabled individuals, to accommodate advanced therapies that were once experimental but are now part of standard care for some conditions.
Medicare’s coverage decisions influence how private insurers respond, shaping access across the health system. Private insurers, including UnitedHealthcare and Anthem, also cover CAR-T therapy, though prior authorization is often required.
The payment system, however, is still catching up with the complexity and cost of the treatment. The August 2019 Medicare mechanism was a first step, but as more CAR-T therapies reach patients, their cost and the resource-intensive nature of their delivery force broader questions about how health systems can sustainably deliver cutting-edge care without limiting access to those who might benefit most. The bottom line, according to the study and insurance data, is that CAR-T therapy is here to stay, and the financial infrastructure for it remains a work in progress.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CAR-T cancer therapy costs up to $1.2 million in first year”, “description”: “WASHINGTON, July 14 — The first year of treatment for a single patient receiving chimeric antigen receptor T-cell therapy, or CAR-T, can reach $1.2 million…”, “datePublished”: “2026-07-14T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Sophie King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
